论文信息 - Final results: A dose escalation phase I study of ARQ 197, a selective c-Met inhibitor, in patients with metastatic solid tumors. - 字舞流文

Final results: A dose escalation phase I study of ARQ 197, a selective c-Met inhibitor, in patients with metastatic solid tumors.

N. Senzer | T. Mekhail | L. Rosen | R. Savage | F. Chai | T. Rich | Z. Semic-Suka | Lee S. Rosen | Ronald E. Savage | Neil N. Senzer